Amprenavir

spinqualitylabelsall models Amprenavir, better known as Agenerase, (3nu4) Show:Asymmetric Unit Biological Assembly Drag the structure with the mouse to rotate   Export Animated Image   Print3D Better Known as: Agenerase Marketed By: GlaxoSmithKline Major Indication: Human Immunodeficiency Virus Infection Drug Class: HIV Protease Inhibitor Date of FDA Approval (Discontinued): 1999 (2004) 2004 Sales: ~$50 Million Importance: It was the first HIV Protease inhibitor which required only twice-a-day dosing as opposed to every 8 hours. It was replaced by a longer acting prodrug version called Fosamprenavir. See Pharmaceutical Drugs for more information about other drugs and diseases. Mechanism of Action When HIV first infects someone, it directs the synthesis of several polyproteins. The maturation of the virus to its infectious form requires that these polyproteins be cleaved to their component proteins by HIV Protease. The subunits of HIV Protease come together to form a catalytic tunnel capable of tightly binding the nascent peptides and cleaving them into their mature, infectious form. Within this tunnel lies two Asp-Thr-Gly conserved sequences, which contain the catalytic Asp residues. These catalytic Asp residues carry out the hydrolytic cleavage of the polyprotein. Amprenavir binds specifically to these conserved sequences within the HIV Protease tunnel, preventing the nascent polyproteins from entering. Unable to actively cleave the nascent proteins into their infectious form, HIV is unable to mature and proliferate, allowing the patients immune system to fight off the infection more easily. Drug Resistance The biggest difficulty with treating HIV is the rapidity at which it mutates and becomes resistant to treatments. To view a comprehensive and interactive analysis of the mutations which confer drug resistance to HIV Protease, See: HIV Protease Inhibitor Resistance Profile

Pharmacokinetics

HIV Protease Inhibitor Human Immunodeficiency Virus Parameter HIV Protease HIV Protease Fosamprenavir Pharmaceutical Drugs Amprenavir HIV HIV Protease HIV HIV Protease HIV Protease Inhibitor Resistance Profile Tmax (hr) 4.4 ~3 1.5 3.7 .98 1.5-4 2 .5 2-4 3.1 Cmax (ng/ml) 13120 14600 8100 2297 4901 4820 11.9 2730 ~4393 4701 Bioavailability (%) -- -- 65 4 -- -- -- -- 68 20-80 Protein Binding (%) 99 >99 61 98 90 90 99 95 86 98 T1/2 (hr) 4.8 4.2 1.2 4.5 5.5 7.7 6.1 29.4 5.3 3.3 AUC (ng/ml/hr) 128100 46500 20900 13467 11999 35000 117600 4746 ~26045 31906 Clearance (L/h) ~8.4 32.4 49.5 36.7 56.8 84.4 1.7 32.8 13.6 37.3 Dosage (mg) 600 600 800 1000 600 1400 280 400 400 1250 Metabolism Hepatic (CYP3A4 & CYP2C19) Hepatic (CYP3A4) Hepatic (CYP3A4) Hepatic (CYP3A4 & CYP3A5) Hepatic (CYP3A4) Hepatic (CYP3A4) Hepatic (CYP3A4) Hepatic (CYP3A4) Hepatic (CYP3A4) Hepatic (CYP3A4) For Pharmacokinetic Data References, See: References

Proteopedia Page Contributors and Editors (what is this?)

David Canner, Alexander Berchansky